How Much Is Mounjaro? Uses, Cost, and Context

This guide lives in the PlexusDx Education Hub, our library of evidence-based reading on GLP-1 pathways, weight management, and the genetics behind metabolic decisions.

People typing "how much is Mounjaro" are often asking more than a price. They want a plain-language orientation: what the drug is, how it works, what it is for, what to expect, and roughly what it costs. This overview handles each of those in turn and links to the more specific guides for deeper dives, so you can start broad and then narrow to the question that actually matters to you.

What Mounjaro is

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist. The same molecule is FDA-approved for type 2 diabetes as Mounjaro, for chronic weight management as Zepbound, and for obstructive sleep apnea in adults with obesity as Zepbound (2024). The dual GIP and GLP-1 mechanism is the molecule's defining feature and is what distinguishes it from single-pathway agonists.

How the mechanism works

GLP-1 receptor agonists engage the GLP-1 receptor in the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. As a dual agonist, tirzepatide additionally engages the GIP receptor, adding a second incretin mechanism. Dosing by compound, weekly or daily, delivers sustained receptor engagement over time.

What it is used for

FDA-approved indications across this class include type 2 diabetes for most compounds, chronic weight management for products such as Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound (2024). Prescribing matches the brand's FDA-approved indication; the same molecule under a different brand is not automatically interchangeable for insurance or coverage.

Common side effects

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation are the most commonly reported effects and tend to be most pronounced during dose titration. All FDA-approved GLP-1 compounds carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the setting of dehydration.

What it costs

Manufacturer list prices for FDA-approved branded products in this category typically run $800 to $1,600 per month at U.S. list as of April 2026. Actual out-of-pocket cost depends on insurance coverage, the FDA indication on the prescription, manufacturer savings card eligibility, and whether a compounded alternative is available through a licensed 503A pharmacy pathway. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols with per-protocol pricing published on each product page.

Where your genetics fit in

Whatever brand enters the conversation, the underlying architecture is the same. The Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights, reading pathway-level variants such as FTO, GLP1R, MC4R, TCF7L2 that shape appetite signaling, energy balance, and baseline metabolic tendencies. It is trait and pathway education only. It does not predict how you will respond to any specific medication, and it is not a drug-response test. Think of it as the biological backdrop your provider reads before any conversation about a protocol.

How the brands relate to each other

One source of confusion is that the same molecule wears different brand names, and the names are not interchangeable for coverage. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity. That means a plan can cover one brand and not another even though the underlying compound is identical, because prescribing and coverage follow the brand's specific FDA-approved indication. Understanding this prevents a common mistake: assuming that because a molecule is approved somewhere, it is automatically covered for your situation. When you see prices or coverage discussed online, check which brand and which indication the figure assumes, because that context determines whether it has anything to do with your own prescription and plan.

Frequently Asked Questions

What is Mounjaro, in one sentence?

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist FDA-approved for type 2 diabetes, with the same molecule approved as Zepbound for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity. Prescribing matches the brand to its approved indication.

How does the dual agonist mechanism differ from GLP-1 alone?

A GLP-1 agonist engages the GLP-1 receptor to slow gastric emptying, blunt glucose spikes, and increase satiety. Tirzepatide adds engagement of the GIP receptor, a second incretin pathway. That dual action is the defining feature of the molecule and what separates it from single-pathway agonists.

What are the most common side effects?

Gastrointestinal effects, nausea, vomiting, diarrhea, and constipation, are most commonly reported and typically peak during titration. The class carries a boxed warning for thyroid C-cell tumor risk seen in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury. Discuss your history with a provider.

Roughly what does it cost per month?

Branded FDA-approved products in this category typically list at $800 to $1,600 per month at U.S. list as of April 2026. What you actually pay depends on coverage, the prescription indication, savings card eligibility, and whether a compounded pathway applies. Confirm current figures with the pharmacy before filling.